Accessibility Menu
Silo Pharma logo

Silo Pharma

(NASDAQ) SILO

Current Price$4.88
Market Cap$5.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-97%
1 Year-47%
1 Month-24%
Silo Pharma last closing stock price
MetricPriceDate
Last closeUSD 4.782026-07-16
Silo Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-38.16%USD 7.732026-07-09
1 month-23.52%USD 6.252026-06-16
3 month-38.12%USD 7.732026-04-17
Year to date-6.27%USD 5.102025-12-31
1 year-46.9%USD 9.002025-07-16
3 year-84.38%USD 30.602023-07-17
5 year-96.81%USD 150.002021-07-16
Since inception-99.73%USD 1,762.502014-05-13

Silo Pharma Financials at a Glance

Market Cap

$5.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$72.10K

Net Income (TTM)

-$4.84M

EPS (TTM)

-$7.46

P/E Ratio

-0.64

Dividend

$0.00

Beta (Volatility)

0.65 (Low)

Price

$4.88

Volume

160

Open

$4.88

Previous Close

$4.78

Daily Range

$4.77 - $5.00

52-Week Range

$3.32 - $15.15

Estimated Earnings Date

Sep 2, 2026

SILO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Silo Pharma

Silo Pharma develops new medicines for mental health and chronic pain. Its main products target conditions like post-traumatic stress disorder and fibromyalgia. These treatments aim to help people who do not respond to existing therapies.

Lab Coats and Licenses: Silo’s Product Lineup

  • SPC-15 (PTSD/Anxiety): Intranasal treatment for post-traumatic stress and anxiety.
  • SP-26 (Chronic Pain): Time-release implant with ketamine for fibromyalgia and long-term pain relief; preclinical stage.
  • SPC-14 (Alzheimer’s): Intranasal compound for Alzheimer’s disease; targets cognitive and neuropsychiatric symptoms, preclinical.
  • SPU-16 (Multiple Sclerosis): Peptide therapy for multiple sclerosis and related nerve disorders; preclinical, under exclusive option.
  • Digital Asset Treasury: Cryptocurrency treasury strategy (Bitcoin, Ethereum, Solana) as a new capital management approach, starting August 2025.

Growth Spurts and Side Quests: Silo’s Expansion Moves

  • Signed exclusive license with Columbia University for SPC-15 and SPC-14 in June 2024.
  • Entered exclusive option with University of Maryland, Baltimore for SPU-16 in July 2025.
  • Launched cryptocurrency treasury strategy and advisory board in August 2025.
  • Acquired web-based software and domains (r2crypto.com, socialscan.info, coinfeel.net) in July 2025.
  • Submitted pre-IND package for SPC-15 to FDA in June 2024; pre-IND meeting held September 2024.

What Makes Silo Pharma Stand Out

Silo Pharma focuses on both traditional and psychedelic-based medicines for hard-to-treat conditions. It uses unique drug delivery methods, like nasal sprays and implants, to target specific diseases. The company relies on academic partnerships and a lean team to advance its pipeline.

Five Things You Need to Know

  • Revenue was $18,025 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • 100% of revenue comes from a single licensee, Aikido Pharma, as of June 2025.
  • Net loss was $1.2 million in Q2 2025, up 29.2% from Q2 2024.
  • R&D expense was $717,247 in Q2 2025, up 82.6% from Q2 2024.
  • Cash and short-term investments totaled $6.3 million as of June 30, 2025.

Bottom Line

Silo Pharma is a small biotech firm focused on new therapies for mental health and pain. Its strategy combines academic partnerships, licensing, and digital asset management to diversify its business model.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Eric Weisblum

Website

www.silopharma.com

Headquarters

Sarasota, FL 34236, US

SILO Financials

Key Financial Metrics (TTM)

Gross Margin

-328.69%

Operating Margin

-6631.16%

Net Income Margin

-6717.40%

Return on Equity

-88.41%

Return on Capital

-67.89%

Return on Assets

-69.01%

Earnings Yield

-1.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.13M

Volume

160

Avg. Volume

207.71K

Financials (TTM)

Gross Profit

-$236.99K

Operating Income

-$4.78M

EBITDA

-$4.79M

Operating Cash Flow

-$3.84M

Capital Expenditure

$6.00

Free Cash Flow

-$3.84M

Cash & ST Invst.

$6.27M

Total Debt

$0.00

Silo Pharma Performance Analysis

Silo Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 72,1021.2%
20232023-12-31USD 72,1020.0%
20242024-12-31USD 72,1020.0%
20252025-12-31USD 72,1020.0%
Silo Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-0.0%
Q32025-09-30N/A
Q42025-12-310.0%
Q12026-03-31N/A
Silo Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -25.67N/A
20232023-12-31USD -18.02-29.8%
20242024-12-31USD -17.90-0.7%
20252025-12-31USD -7.57-57.7%
Silo Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3017.4%
Q32025-09-3036.8%
Q42025-12-3144.8%
Q12026-03-31-81.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$18.03K

+0.0%

Gross Profit

-$248.23K

-1598.4%

Gross Margin

-13.77%

N/A

Market Cap

$5.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.80M

N/A

Employees

3

N/A

Net Income

-$1.65M

-59.7%

EBITDA

-$1.64M

-59.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.27M

+15.1%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-69.01%

N/A

Return on Invested Capital

-75.73%

N/A

Free Cash Flow

-$822.62K

+49.8%

Operating Cash Flow

-$822.62K

+49.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNGXSoligenix, Inc.
$0.36-3.31%
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%
INMInMed Pharmaceuticals Inc.
$1.59+0.00%
CNSPCNS Pharmaceuticals, Inc.
$4.74+1.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$207.33-0.02%
AAPLApple
$333.13+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
NUNu Holdings
$13.78-0.01%

Questions About SILO

What is the current price of Silo Pharma?

Silo Pharma is trading at $4.78 per share.

What is the 52-week range for Silo Pharma?

Over the past 52 weeks, Silo Pharma has traded between $3.32 and $15.15.

How much debt does Silo Pharma have?

As of the most recent reporting period, Silo Pharma reported total debt of $0.00.

How much cash does Silo Pharma have on hand?

Silo Pharma reported $3.90M in cash and cash equivalents in its most recent financial results.

What is Silo Pharma’s dividend yield?

Silo Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services